GMAB vs. GSK: Genmab vs. GSK Stock Comparison

Company Profile

Genmab (GMAB) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while GSK is classified in Pharmaceuticals.

Both Genmab (GMAB) and GSK (GSK) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Genmab (GMAB) at 12.07% and GSK (GSK) at 28.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Genmab (GMAB) at 16.97% and GSK (GSK) at 12.97% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Genmab (GMAB) at 37.15% and GSK (GSK) at 32.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Genmab (GMAB) at 19.19% and GSK (GSK) at 4.11% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Genmab (GMAB) at -9.23% is closer to the peer norm — faster per-share earnings growth for GSK.

Growth Metrics

Financial Strength

Both Genmab (GMAB) at 2.45 and GSK (GSK) at 0.86 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Genmab (GMAB) at 0.82 and GSK (GSK) at 1.30 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Genmab (GMAB) at 7.68 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Genmab (GMAB) at 5.36 and GSK (GSK) at 4.02 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics